Effect of Inhaled Interferon Beta-1a on Carbon Monoxide Transfer Factor in Healthy Volunteers
- 1 February 2016
- journal article
- research article
- Published by SAGE Publications in Journal of Interferon & Cytokine Research
- Vol. 36 (2) , 113-119
Abstract
Interferon beta-1a (IFNβ-1a) 30 μg weekly by intramuscular (IM) injection is used to treat relapsing forms of multiple sclerosis. We assessed if it can be given safely by inhalation. Twenty-one healthy volunteers inhaled IFNβ-1a 300 μg, formulated for deep delivery to the lungs, in a randomized, parallel-group, repeat-dose trial. Comparators were room air and placebo. The primary outcome measure was carbon monoxide transfer factor corrected for hemoglobin (TLCOc), which measures the CO transfer from inspired gas to pulmonary capillary blood. After 3 and 4 once-weekly doses, IFNβ-1a significantly reduced TLCOc compared with room air: after the third dose, mean standard deviation (SD) change in percent predicted TLCOc was−10.9 (2.8), and after the fourth dose was−12.1 (2.7). After 2, 3, and 4 doses, IFNβ-1a significantly reduced TLCOc compared with placebo: after the second dose, mean (SD) change in percent predicted TLCOc was−8.8 (5.5), after the third dose was−10.9 (2.8), and after the fourth dose was−12.1 (2.7). Circulating IFNβ-1a concentrations were about one-third those of the intramuscular dose regimen. Tolerability of IFNβ-1a and the comparators was equally good. In conclusion, IFNβ-1a reduced TLCOc, whereas placebo and room air did not. A dose of IFNβ-1a 300 μg by inhalation may not be safe for general use.Keywords
This publication has 20 references indexed in Scilit:
- The Effect of Inhaled IFN-β on Worsening of Asthma Symptoms Caused by Viral Infections. A Randomized TrialAmerican Journal of Respiratory and Critical Care Medicine, 2014
- Delivery and Safety of Inhaled Interferon-γ in Idiopathic Pulmonary FibrosisJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2012
- Ingested Type I Interferon—State of the Art as Treatment for Autoimmunity Part 2Pharmaceuticals, 2010
- Meta-Analysis: Efficacy and Safety of Inhaled Insulin Therapy in Adults with Diabetes MellitusAnnals of Internal Medicine, 2006
- Treatment satisfaction in type 2 diabetes: A comparison between an inhaled insulin regimen and a subcutaneous insulin regimenClinical Therapeutics, 2002
- Effects of Aerosolized Interferon- α in Patients with Pulmonary TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Minimal dose of aerosolized interferon-alpha in human subjects: biological consequences and side-effectsEuropean Respiratory Journal, 1996
- American Thoracic Society. Single-Breath Carbon Monoxide Diffusing Capacity (Transfer Factor). Recommendations for a Standard Technique--1995 UpdateAmerican Journal of Respiratory and Critical Care Medicine, 1995
- Inhaled recombinant interferon gamma in patients with lung cancer: Pharmacokinetics and effects on chemiluminescence responses of alveolar macrophages and peripheral blood neutrophils and monocytesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995
- Pharmacokinetics and Toxicity of Inhaled Human Interferon-α in Patients with Lung CancerJournal of Interferon Research, 1989